The purpose of this document is to develop recommendations on the use of the latest generation of cardiac troponins in emergency room settings for the diagnosis of myocardial infarction in patients with suspected acute coronary syndrome (ACS) without persistent ST-segment elevation (NSTE-ACS). The main points which have been addressed reaching a consensus are represented by: 1. Suitability and appropriateness of the terminology. 2. Appropriateness of the request. 3. Confirmation of the diagnosis of myocardial infarction (rule-in).
Work method: Each point has been analyzed by taking into account the evidence presented in medical publications. Recommendations were developed using the criteria adopted by the European Society of Cardiology and the American Heart Association/American College of Cardiology (www.escardio.org/guidelines). Each point of the recommendation was submitted for validation to an external audit by a Group of Experts (named above).
which recommends, as a decision level for the diagnosis of AMI, cTnI and cTnT elevations greater than the 99th percentile of distribution values measured in a reference population consisting of apparently healthy individuals free from heart disease. The same guidelines recommend that such a decision level must be measured with an imprecision less than or equal to 10% [coefficient of variation (CV)]. These quality specifications for the determination of cardiac troponins were confirmed initially by a task force from the National Academy of Clinical Biochemistry (NACB) and International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine and -more recently -by an interdisciplinary study group organized by the European Society of Cardiology (ESC) [3, 4] . At the time of publication of the first consensus document [1] , the recommended quality specifications were not satisfied by commercially available methods for measurement of cTnI and cTnT [5, 6] . Only recently, in fact, some methods for cardiac troponin assay, characterized by an improved analytical sensitivity (i.e., high-sensitivity assay), entered the marketplace [6] . It is noteworthy that one should define as newer high-sensitivity methods for the measurement of cardiac troponins cTnI and cTnT only those immunometric techniques that are able to measure the 99th percentile of the distribution of proteins cTnI and cTnT in the reference population with an error (expressed as a CV) equal to or lower than 10%, as currently required by international guidelines [1] [2] [3] [4] . These assays should also be able to measure the levels of cTnI and cTnT in most adult subjects in apparent good health. In accordance with a recent article by Apple [7] , one should classify the sensitivity of the methods of the latest generation into four levels depending on the proportion of apparently healthy subjects in which it is possible to measure the analyte concentrations (Table 1 ). As such, only methods that measure the cTnI and cTnT concentrations in most healthy subjects (i.e., > 75%) should be defined as high hs, high sensitivity; high-sensitivity methods (according to [7] ).
sensitivity. The denomination of ultra-sensitive methods should therefore be abandoned, because there is no reliable analytical basis to support the use of this term. The study group of the ESC [4] has recently concluded that the reference population on which to calculate the 99th percentile of the distribution of the values of cTnI and cTnT should consist of at least 300 apparently healthy subjects of both genders and distributed according to a broad age distribution. In addition, these subjects should result negative in a stress test and possess cardiac function within normal limits, as assessed by means of cardiac imaging.
Unfortunately, these recommendations are difficult to implement at the local level by individual laboratories, principally because of the difficulty in recruiting a carefully selected wide target population. Individual laboratories may adopt as reference values those suggested by manufacturers or reported by recent scientific papers with the same technique, and which have been determined on a suitable number of healthy adults [6] [7] [8] [9] [10] [11] [12] [13] [14] . However, it is well known that the concentrations of cTnI and cTnT are higher in males than in women of the same age, and tend to increase progressively beyond 60 years [6] [7] [8] [9] [10] [11] [12] [13] [14] . It follows that the calculated value of the 99th percentile varies considerably depending on the demographic characteristics of the reference population considered [6] . It is also noteworthy that the average age of the reference population on which the 99th percentile was calculated ranged from 37 [14] to 59 [12] years, according to the study. By contrast, the average age of patients presenting to the emergency department with chest pain and suspected ACS can vary from 52 to 62 years, depending on the studies [15] [16] [17] and, in clinical practice, it may be even higher. A Canadian study investigated the age of 54,134 patients who presented to the emergency department between 1998 and 2001 with chest pain and/or suspicion of ACS, reporting that patients with unstable angina or AMI had a higher average age of some 10-15 years compared to those without acute ischemic cardiac complications [18] .
It is noteworthy that the cTnI is measured by various methods, distributed by different manufacturers, and that therefore the measured levels vary considerably (even more than 20 times) from method to method, as well as the reference values [5] . By contrast, cTnT is currently being measured by the same analytical procedure, and thereby presents practically the same values and the same reference limits, even using different automated platforms. Table 2 shows some analytical characteristics and 99th percentile values of the reference population of some cTnI and cTnT methods. Unfortunately, there are conflicting results in the literature concerning the analytical characteristics LoD, limit of detection; LoQ, limit of quantitation (functional sensitivity) at 10% CV level.
of cTnI methods [8] [9] [10] . These differences are due both to different experimental protocols used for the calculation of LOD and LOQ values and to different versions of evaluated methods (e.g., prototype instead of commercially available version) [5, 6, [8] [9] [10] 19] . In Table 2 , only the analytical characteristics of the more diffuse cTnI methods at present time commercially available in Italy are reported. Since cTnT and cTnI are different molecules, the results are not interchangeable, nor directly comparable [20] . The high degree of analytical sensitivity of the newer methods allows also the evaluation of the biological variation of circulating levels of cTnI and cTnT in healthy subjects [21] or patients with cardiomyopathy [22] . As a result, it is possible to calculate the reference change value (RCV), which is related to both biological variation and analytical imprecision. For many analytical methods, the RCVs vary in a range from 40% to 60% up to 86%. It is very likely that in the presence of minor variations of cTnI and cTnT (e.g., 20% at concentration below the reference range), it is possible to rule-out an acute event. In cases of strong clinical suspicion or high pre-test probability it is recommended, under these conditions, that the test should be repeated after a few hours (typically between 3 and 4 h) [4] .
Recommendations

One should define methods of the latest generation
for the determination of troponins cTnI and cTnT only those immunometric assays that measure the 99th percentile of the distribution of proteins cTnI and cTnT in the reference population with an error (expressed as CV) equal to or lower than 10%, as required by international guidelines [1] [2] [3] [4] . That error should be expressed as a CV. The latest generation methods showing an intermediate imprecision (10%-20%) should be considered clinically usable. 2. One should define methods of the latest generation of high sensitivity only those methods that measure the levels of cTnI and cTnT in the majority of apparently healthy adults who compose the population of normal reference range. 3. The reference population on which the 99th percentile of the distribution of the values of cTnI and cTnT is calculated should consist of at least 300 apparently healthy subjects of both genders, and according to a broad age distribution [4] . This reference population should also have demographic characteristics as similar as possible to patients who present to the emergency department with chest pain and suspected ACS.
Appropriateness of the troponin test request
The advent of biomarkers assessment in the context of diagnosis of chest pain has provided the emergency physician with an important tool to quickly identify patients with suspected ACS. The recent introduction of new methods for assessment of biomarkers of myocardial necrosis, in particular the latest generation of cardiac troponins, has allowed the identification of increasingly large areas of biochemistry positivity, which is not always securely attributable to the context of myocardial ischemia. The increased sensitivity of the test, in fact, inevitably causes a lower specificity for ischemic damage.
It is therefore increasingly common to detect a value exceeding the upper reference limit (99th percentile) of the latest generation of troponins that is not necessarily ischemic in origin. These troponins have, in fact, a high specificity for myocardial injury but not for AMI (low positive-predictive value). For this reason it is essential that the emergency physician has broad awareness about the diagnostic maze of chest pain, using the markers appropriately.
The diagnosis of AMI in patients with normal or non-diagnostic ECG (generally referred to as NSTEMI, i.e., without ST-segment elevation) should be based on the correct interpretation of the values of cTn, in particular its release kinetics, distinguishing myocardial damage caused by myocardial ischemia from myocardial injury caused by other factors. Evidence to support this possibility is still somewhat preliminary so far [1] .
The evaluation of chest pain patients with a nondiagnostic ECG in the emergency department is a dynamic and articulate process, wherein the use of marker should be targeted and guided especially as to the probability (i.e., likelihood) of disease [2] . To avoid excessive use of this biomarker, it should be measured only in patients with chest pain who have a pre-test probability, albeit low, of suffering from myocardial infarction [3] . It is necessary to systematically correlate symptoms, clinical presentation and likelihood of disease [3] [4] [5] . In particular, it is suggested to investigate all those patients with at least one risk factor of coronary artery disease (CAD), even when associated with atypical chest pain and those patients with no risk factors for CAD but with typical chest pain.
Many patients, however, present with symptoms other than chest pain (atypical presentation), such as isolated dyspnea, transient palpitations, sudden fatigue, nausea/ vomiting, diaphoresis, an acute confused state and syncope [6] [7] [8] [9] [10] . In the study by Canto et al. [11] the variables associated with a presentation characterized by the absence of chest pain were: history of heart failure or stroke, older age ( > 75 years), diabetes mellitus, female gender and a race other than white. In this study, only 17% of AMI patients without these risk factors had no chest pain at presentation, however, patients with at least three risk factors had a 50% or greater chance of not having chest pain at presentation. Patients with AMI and atypical presentation, with the exception of those with diaphoresis, are at high risk of death. The isolated dyspnea, particularly in diabetic patients and in the elderly, may be the only presenting symptom in the course of an ACS which is worsened by its high mortality rate [11, 12] . The appearance of palpitations, in particular from ventricular arrhythmia, has been linked by some authors with a manifestation of myocardial ischemia in the elderly population [13] . Sudden fatigue can be a symptom that precedes or accompanies AMI in the absence of chest pain, particularly in diabetic patients [14] [15] [16] . A syncope onset without prodromes should be considered suspect inasmuch as the cause may be the onset of ventricular arrhythmia following acute coronary ischemia [17] . Due to the aforementioned reasons, a call to standardize symptom presentation in ACSs has recently been advocated. As such, rather than accepting descriptions as typical or atypical symptoms, it is now considered imperative to elucidate the entire ACS symptom complex [18] . It is therefore appropriate to test troponin in patients presenting in the emergency department for ongoing or previous chest pain (regardless of the a priori probability of coronary heart disease), but also in those who report atypical symptoms in the presence of high-risk conditions already mentioned (associated or not with electrocardiographic abnormalities). These patients are at high risk in cases where the diagnosis of myocardial infarction is confirmed. It is inevitable that this approach emphasizes the sensitivity of the diagnosis with respect to the specificity, with possible implication of increased workload and operating costs.
Recommendations
1. The measurement of cardiac troponins should be requested in patients presenting to the emergency department with ongoing or previous chest pain. 2 . The measurement of troponin should be considered in patients without chest pain, but who have one of the following symptoms considered equivalent to angina: sudden onset isolated dyspnea, diaphoresis, palpitations, nausea/vomiting, sudden fatigue, an acute confused state or syncope. These symptoms lead to the suspicion of ACS. 3. In case of symptoms listed in paragraph 2, the measurement of troponin should be requested in patients with at least one of the following conditions: previous stroke, previous heart failure, advanced age ( > 75 years) diabetes mellitus, female gender. 4. The assessment of troponins measured with the latest generation assay, characterized by improved diagnostic sensitivity, makes it inappropriate and virtually useless the contextual request of additional biochemical markers of myocardial ischemia and/or injury (e.g., myoglobin, creatine kinase MB, and others) [19] . 
Biochemical confirmation of the diagnosis of myocardial infarction (rule-in)
The introduction in the market of new methods, with improved analytical sensitivity [1] requires the redefinition of the diagnostic approach of suspected NSTE-ACS in terms of application of the biochemical algorithms used so far. Currently, we know that an increase above the cut-off in patients without typical ECG changes implies the same prognosis as overt STEMI. However, the optimal timing of coronary intervention for NSTEMI is still under debate. NSTEMI will change considerably with these new troponins assays and further interventions studies should be performed.
The most discussed aspects in the application of these improved analytical methods in clinical practice mainly concern: 1. The time of blood sampling; 2. The cut-off concentrations used for the diagnosis of AMI; 3. The amount of changes of troponin concentrations found in consecutive samples necessary to make the diagnosis of AMI.
In this regard, some observations are important: 1. The improved analytical sensitivity allows accurate measurement of protein concentrations nearly 5-20 times lower than those measured using previous generation methods. Accordingly, the concentration measured upon admission may already be suggestive of myocardial infarction in a significantly larger percentage of patients. In addition, it can be expected that troponin concentrations change very rapidly within shorter time intervals [1, 2] . 2. The availability of methods able to measure the protein concentration in a population of healthy subjects implies a decision making level (cut-off) corresponding to the 99th percentile. 3. There are several, not necessarily ischemic, clinical conditions (Table 3) , associated with increased troponin concentrations, and which make it necessary a differential clinical and biochemical diagnosis, based on the evaluation of the kinetics of release and/ or extent of increase.
Recommendations
Based on analytical considerations and troponin concentration on admission (baseline sampling T0), in the clinical context of chest pain, the following diagnostic algorithms may be recommended [3, 4] ( Figures  1 and 2 ):
1. Troponin on admission (T0) at or above the 99th percentile: serial sampling at intervals of 3 h (T1, highsensitivity methods) or 6 h (T1, latest generation methods).
The blood sample at the sixth hour may be optionally considered for high-sensitivity methods. Interpretation: the kinetics are suggestive of acute myocardial necrosis if the increase of concentration in the blood samples after 3/6 h (T1) is greater than or equal to 50% of the baseline value (T0). 2. Troponin on admission (T0) at or below the 99th percentile: serial sampling at intervals of 3 h (T1, highsensitivity methods) or 6 h (T1, latest generation methods). The blood sample at the sixth hour may be optionally considered for high-sensitivity methods.
Interpretation: the kinetics are suggestive of acute myocardial necrosis if the concentration in the blood sample after 3/6 h (T1) is greater than or equal to 99% percentile and the extent of the increase is greater than or equal to 50% of the baseline value (T0).
AMI should be diagnosed in patients showing concentration changes as described in points 1 and 2, when associated with clinical context of myocardial ischemia (based on the symptoms and/or ECG changes and/or the finding of imaging techniques).
The percentage of increase recommended above takes account of current analytical performance of most of the methods commercially available, which measure the concentration at the 99th percentile with an imprecision of about 20%. The use of the RCV calculated from studies of biological variability, needs further confirmation, because the published data are conflicted and only available for some methods [5] [6] [7] .
It has been proposed that the significance of the percentage increase may vary according to the baseline concentration: 20% for values equal or above the 99th percentile, 50% for baseline values below 99th percentile, 10% for values significantly increased at the presentation [2, [8] [9] [10] . The choice of the 50% variation compared to basal value (Recommendations 1 and 2, as well as Figures 1 and 2) should be considered to be the best compromise taking into account both the biological variation of troponins and the imprecision of the major part of the methods at present time commercially available in Italy. Of course, the use of 50% variation increases test specificity but also decreases test sensitivity in respect to the use of a lower percent variation (such as 20%) [2] . As a result, in some specific clinical setting, the choice of a lower percent variation may be preferable.
Recent studies [11] [12] [13] [14] [15] [16] have shown that the variation in absolute value of the concentration of troponin, allows a more accurate diagnosis than the percentage change, especially for values close to the 99th percentile. Nevertheless, since this variation is method-dependent, it is not possible to provide a concentration value applicable to all methods available on the market and the former approach is thereby preferable also for purposes of harmonization. 
Biochemical exclusion of myocardial infarction (rule-out)
It is essential for the emergency physician to rapidly ruleout AMI and to discharge the patient with reasonable safety, particularly in those cases where he/she may have presented with chest pain and normal or non-diagnostic ECG. As for the rule-in, it is essential to establish the timing of assessment of serum troponin value. In cases where the value of troponin is normal in the established time intervals, the patient may be discharged with reasonable confidence if the probability of ACS, at the end of the observation period, is sufficiently low (Table 4 ). In case of troponin elevation and in the presence of conditions associated with persistently increased values (e.g., renal failure), it is necessary to establish the percentage increment below which it is reasonable to conclude that myocardial damage is caused by a chronic rather than an acute condition and, possibly, that the variation is not attributable to myocardial necrosis secondary to an acute ischemic event. We suggest an observational period of not less than 6 h before discharging patients safely, considering the first assessment (T0) at the admission to the emergency department [1] . Discharge can be considered only for patients with low or intermediate probability of ACS (Table 4) . For troponins measured by using the latest generation methods -but not of high sensitivity -in patients admitted to the emergency department, the following schedule can be proposed (Figure 3 ): 1. The first determination is the time of arrival in the emergency department (considered as T0); 2. The second determination is obtained after 6 h.
In the case of patients with low or intermediate probability/risk of disease, if after 6 h the concentration of troponin does not exceed the 99th percentile or does not show a significant kinetic increment ( < 50%), the diagnosis of AMI is highly unlikely and the patient is at low risk of adverse events in the short-term; persistently negative troponin concentrations during the observation identify a low-risk population for which it is possible to assume a fairly safe rule-out of AMI if non-coronary acute cardiac conditions can be excluded. These patients may be discharged with an outpatient indication stress test within the shortest time.
If troponins are measured using high-sensitivity methods, the following schedule of blood samples can be recommended [2] (Figure 4 ): Table 4 Probability of ACS secondary to coronary artery disease based on signs and symptoms at presentation. Myocardial infarction "unlikely" 1. The first determination is the time of arrival in the emergency department (considered as time 0); 2. The second determination after 3 h.
High likelihood
If after 3 h the concentration of hs-Tn does not exceed the 99th percentile, the diagnosis of AMI is unlikely [1] [2] [3] and it is highly unlikely if the concentration of hs-Tn remains constantly below the limits of analytical sensitivity [4, 5] .
In cases where the increase of the concentration is less than the percentage increment considered significant ( ≥ 50% variation from baseline) for myocardial infarction and concentrations do not exceed the 99th percentile, a second blood sample is indicated at the sixth hour [3, 6] . If at this time point the value does not exceed the 99th percentile, patients can be classified as at low risk of adverse events and may be discharged with an outpatient indication stress test within a short time.
Recommendations
1. To rule-out of AMI, the assessment of troponin measured by the latest generation methods, should be performed at time 0 (arrival in the emergency department) and after 6 h. If all the values observed are ≤ 99th percentile or the variation concentration is < 50% (below the 99th percentile), the patient can be discharged. 2. When using high-sensitivity methods, it is recommended to assess troponin values at time 0 and after 3 h. When both values are below the limit of analytical sensitivity, the patient may be discharged.
When both values are < 99th percentile and the patient is at low or intermediate probability of ACS, the patient can be discharged if different acute cardiac conditions can be ruled out. Patients with recurrent symptoms and high probability of coronary heart disease should be kept under observation over 3-6 h, or until a final diagnosis has been reached.
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